Financial reports
In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.
Copyright applies to all footage.
CombiGene AB (publ): Valberedning
Valberedning har i enlighet med årstämmans beslut 2020 bildats Årsstämman 2020 beslutade att valberedning skulle tillsättas enligt följande: ”Valberedning ska bestå av representanter för de tre röstmässigt största aktieägarna per den 30 september 2020. Om någon av...
read moreExercise period for warrants of series TO4 and TO5 in CombiGene AB (publ) begins today
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Today, the exercise period for subscription of shares in CombiGene AB (publ) ("CombiGene" or the “Company”) begins on the basis of warrants of series TO4 and TO5. Each warrant of series TO4 and TO5...
read moreInterim Report January – September 2020
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Interim Report January – September 2020 for CombiGene AB (publ)för CombiGene AB (publ) About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the...
read moreInterim Report January – June 2020
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Interim Report January – June 2020 for CombiGene AB (publ) >> 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news...
read moreResolutions from the annual general meeting of CombiGene AB, 29 June 2020
Regulatory news 2020 2021 2020 2019 2018 2017 2016 2015 Today, on 29 June 2020, CombiGene AB held its annual general meeting (“AGM”) in Lund. The AGM elected Filip Funk, lawyer at Fredersen Advokatbyrå, as the chairman of the meeting and keeper of the...
read moreAnnual Report 2019
Notice of annual general meeting in CombiGene AB (PUBL)
CombiGene delays the publication of its annual report for 2019
Interim Report January – March 2020
CombiGene’s rights issue subscribed with over 80 percent
CombiGene AB (publ) publishes prospectus in connection with the rights issue
Year-end statement January-December 2019
Interim Report January-September 2019
CombiGene requests initiation of compulsory acquisition proceeding of shares and warrants in Panion
Interim Report January – June 2019
The Report >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish...
read moreAnnual Report 2018
Year-end statement January-December 2018
Interim Report January – September 2018
Interim Report January – june 2018
Interim Report >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden <a href="https://www.linkedin.com/company/10149155/" target="blank"><i class="fa fa-linkedin fa-3x"...
read moreInterim Report January-March 2018
Annual Report 2017
Year-end statement January-December 2017
Interim Report January-September 2017
Interim Report January-June 2017
CombiGene Annual Report 2016
Interim Report January – September 2016
Interim Report January – June 2016
Interim Report January – March 2016
CombiGene Annual Report 2015
Year-end report January-December, 2015
Interim Report January – September, 2015
Interim Report January – March 2015
Annual Report 2014
Annual Report 2012
Annual Report 2013
Find it easy
Presscontact
» press@combigene.com
Press & financial reports
» Pressreleases (MAR) and Financial reports
News
» News
» Ingenious
» Calendar
» Videopresentations
Downloads
» Images
» Logotypes
Newsletter
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden